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In obstructive sleep apnea, patients’ sleep is fragmented leading to excessive daytime 
sleepiness and comorbidities like arterial hypertension. However, traditional metrics are not 
always directly correlated with daytime sleepiness and the association between traditional 
sleep quality metrics like sleep duration and arterial hypertension is still ambiguous. In a 
development cohort, we analyzed hypnograms from mild (n=213), moderate (n=235) and 
severe (n=277) OSA patients as well as healthy controls (n=105) from the European Sleep 
Apnea Database (ESADA). We assessed sleep by the analysis of two-step transitions 
depending on OSA severity and anthropometric factors. Two-step transition patterns were 
examined for an association to arterial hypertension or daytime sleepiness. We also tested 
cumulative distributions of wake as well as sleep states for power laws (exponent α) and 
exponential distributions (decay time τ) in dependency on OSA severity and potential 
confounders. Independent of OSA severity and potential confounders, wake state durations 
followed a power-law distribution, while sleep state durations were characterized by an 
exponential distribution. Sleep stage transitions are influenced by OSA severity, age and 
gender. N2→N3→wake transitions were associated with high diastolic blood pressure. We 
observed higher frequencies of alternating (symmetric) patterns (e.g. N2→N1→N2, 
N2→wake→N2) in sleepy patients both in the development cohort and in a validation cohort 
(n=425). In conclusion, effects of OSA severity and potential confounders on sleep 
architecture are small, but transition patterns still link sleep fragmentation directly to OSA-
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Transitions between wake and sleep and between NREM and REM sleep are based on 
mutually inhibitory neuronal circuits. The complex interactions of different neuronal networks 
result in stable and rapid transitions. (Saper et al., 2010). In obstructive sleep apnea (OSA), 
patients’ sleep is increasingly fragmented, caused by arousals, leading to excessive daytime 
sleepiness (Bianchi et al., 2010; Penzel et al., 2005; Pataka and Riha, 2009). Apart from 
daytime sleepiness, manifold comorbidities and high economic costs are associated with the 
disorder (Parati et al., 2007; Al Ghanim et al., 2008).  
The current polysomnographic evaluation of sleep quality is based upon absolute durations 
like total sleep time (TST) and sleep latencies. However, traditional metrics are not always 
directly correlated with daytime symptoms, such as daytime sleepiness usually assessed 
with the Epworth Sleepiness Scale (ESS), and they are incapable to detect sleep 
fragmentation in OSA patients (Chervin and Aldrich, 1999, Swihart et al., 2008, Bianchi et al., 
2010). Furthermore, the association between traditional sleep quality metrics like sleep 
duration and OSA-related clinical outcomes like arterial hypertension is still ambiguous 
(Pepin et al., 2014). 
Based on this, various approaches have been pursued to develop additional methods to 
understand sleep fragmentation and its clinical potential. Lo et al. described that, across 
different species, the distribution of the duration of wake states follows a power-law, while the 
distribution of sleep state durations follows an exponential law (Lo et al., 2004). Recent 








sleep episode duration was unaltered (Zhang et al., 2017). Furthermore, sleep dynamic 
analysis could distinguish narcolepsy type 1 from type 2 patients (Pizza et al., 2015), 
demarcate patients with chronic fatigue syndrome and those with fibromyalgia (Kishi et al., 
2011) and disclosed a N2 vulnerability in insomnia (Wei et al., 2017). In OSA patients, 
transition analysis revealed more wake to NREM sleep and NREM sleep to wake transitions 
compared to subjects without OSA (Swihart et al., 2008). Furthermore, in children with OSA, 
a shorter mean N2 duration was seen compared to children without OSA (Chervin et al., 
2009). 
A new approach to portray sleep fragmentation is an analysis of transition patterns 
comprising multiple sleep states. A recent study from Schlemmer et al. introduced a two 
step-transition analysis suggesting that the transition probability of the present state is 
affected by the past two states. Two-step transitions comprise three sleep states (e.g. the 
pattern N1→wake→N1). They revealed a modulation of sleep-stage transitions dependent 
on age and sleep disorder. For example, N1→wake→N1 transitions are more frequent in 
older patients with sleep disorder (Schlemmer et al., 2015).   
Based on these reflections, the purpose of our study has been three-fold. First, we have 
hypothesized that, with increasing OSA severity, modified typical transition patterns can be 
observed and that these transition patterns are associated with important OSA related 
outcomes like arterial hypertension or daytime sleepiness. Second, we have aimed to 
evaluate the influence of anthropometric factors on sleep-stage transitions in a large sleep 
apnea patient cohort. Finally, we wanted to confirm that, independent of OSA severity or 
potential confounders, wake states follow a power-law distribution, while sleep states follow 










Our retrospective study is based on data assembled in the frame of the European Sleep 
Apnea Database (ESADA), a collaboration of 28 European sleep centers (Hedner et al., 
2011). Clinical information (e.g. diagnosis of hypertension, systolic and diastolic blood 
pressure in sitting position) and sleep data from OSA patients are registered in a web-based 
report form. For the purpose of this study, 1877 patients from 11 sleep centers were 
assessed: Alexandroupolis, Antwerp, Berlin, Crete, Dublin, Kosice, Milano, Palermo, Paris, 
Thessaloniki and Warsaw. The following exclusion criteria were applied: age under 18 years, 
an apnea-hypopnea-index (AHI) < 5 events per hour, depression or other psychiatric 
disease, narcolepsy, restless legs syndrome, insomnia, opioid-induced central sleep apnea, 
bronchial asthma, fibromyalgia, malignancy or PAP-therapy. Furthermore, patients with 
missing values for ESS, diagnosis of hypertension, systolic or diastolic blood pressure were 
excluded. Based on these criteria, 703 patients (development cohort) from the sleep center 
of Antwerp remained, with a mean age of 49.7±11.0 years, mean BMI of 29.5±5.0 and a 
male predominance (81.1%). In 109 patients central sleep apnea (CSA) of different degrees 
was present. The control group consists of 105 subjects diagnosed as non-apneic snoring 
with an AHI<5/h recorded with polysomnography (PSG) in the sleep center of Antwerp. 
Furthermore, 425 patients (validation cohort) recorded in 10 different centers and registered 
to ESADA have been considered for comparison and validation (mean age 54.0±11.4, mean 
BMI 32.9±6.4, male 78.8%). Patients and controls were assessed according to the ESADA 
protocol (comprising anamnestic report about comorbidity and objective sleep time 








same exclusion criteria. Patients of the development cohort were categorized based on four 
variables: OSA severity, age, gender and BMI. The severity categories were controls 
(AHI<5/h), mild (5/h≤AHI<15/h), moderate (15/h≤AHI<30/h) and severe (≥30/h) disease, see 
also table 1. Based on age, patients were categorized into young (<40y), middle aged 
(40y≥age<60y), and elderly (≥60y). The BMI-group categories were normal weight (BMI<25 
kg/m2), overweight (25kg/m2≤BMI<30 kg/m2) and obesity (BMI≥30 kg/m2). Furthermore, we 
considered gender differences. All patients and controls gave written informed consent. 
Approval was obtained from the Charité ethics committee (EA1/139/07). 
Polysomnography (PSG) 
Our analysis was hypnogram based. In a hypnogram, wake and sleep stages (Wake, N1, 
N2, N3, and REM) were scored visually in 30 seconds epochs based on the AASM scoring 
rules from 2007 (Hedner et al., 2011; Iber et al., 2007). Hypnograms were exported manually 
from the original PSG reports in text or Excel file format (depending on the recording system) 
and then converted into an identical text file format (one number for each epoch) using 
adjusted GNU AWK (Aho et al., 1988) scripts for each sleep laboratory. Afterwards, three 
additional GNU AWK scripts were written and applied to (i) calculate the sleep parameters 
for each hypnogram, (ii) count the frequencies of single-step (e.g. N1→N2) and two-step 
(e.g., N1→N2→N3) transitions, and (iii) determine the distributions of wake-state and sleep-
state durations (see below). The results were further analyzed with Excel [Microsoft] and 
SPSS [IBM Corp. Released 2017. IBM SPSS Statistics for Windows, Version 25.0. Armonk, 
NY: IBM Corp]; plots were created with Origin [www.originlab.com/Origin]. We had to deal 
with some missing sleep parameter values in ESADA. To ensure consistent calculations we 








total sleep time (TST), sleep efficiency (SE), percentages of sleep stages, wake after sleep 
onset (WASO) in min, number of awakenings (NASO) and total number of transitions 
(TRANS). We ignored wake times at the beginning and at the end of the hypnogram, since 
light off and light on times were not available consistently. An apnea was defined by a 
termination of airflow with a minimum length of 10 seconds. A hypopnea was determined 
either by a decrease of airflow ≥50% for at least 10 seconds accompanied by ≥3% oxygen 
desaturation or an arousal or by a decrease of airflow ≥30% for at least 10 seconds 
accompanied by ≥4% oxygen desaturation (Hedner et al., 2011).  
 
Cumulative Distributions 
For each subgroup, we examined whether wake-state durations followed a power-law 
distribution (P(t)=t- α), and whether sleep-state durations followed an exponential distribution 
(P(t)=exp (-t/ τ). The exponential decay time τ corresponds to the mean sleep episode 
duration, whereas the power-law exponent α was observed to be the same in different 
species (Lo, 2004). We simplified each hypnogram into wake bouts and sleep bouts (NREM 
and REM combined) and plotted the cumulative distributions Pi(t), i= W,S of wake and sleep 
versus the duration t. To test qualitatively for superiority of power-law versus exponential 
decay, wake-states have been presented both in a double-logarithmic plot with slopes -α 
representing power-laws and a semi-logarithmic plot with slopes -1/ τ representing 
exponential decays. Sleep states have only been presented in a semi-logarithmic plot. The 
analyzed interval for wake durations was from 1 to 30 minutes and for sleep durations from 3 
to 90 minutes. We fitted the data with both, a power-law distribution and an exponential 








deviations of the data from the fit. Then we used the ratio of fitting errors (χp/χe) as an 
indicator, which distribution law was superior. A ratio larger than unity indicated superiority 
for the exponential fit, while a ratio smaller than unity indicated superiority for the power-law 
fit. For example, if χp (e.g. χp = 0.05) is larger than χe (e.g. χe = 0.005), the ratio of fitting 
errors would be over unity (χp/χe = 10), indicating superiority for exponential distribution. For 
further information about this method, we refer to the work of Zhang et al (Zhang et al., 
2017). 
 
One and Two-step transitions 
The transition analysis was based on symbolic dynamics. Symbolic dynamics is a technique 
that creates patterns by transforming previously confusing information into symbols. This 
process is already established in many scientific fields, e.g. neuroscience or cardiovascular 
physiology (Porta et al., 2015). The classification of sleep in separate sleep stages (Wake, 
N1, N2, N3, REM) is already a depiction in symbols and can be used for further analysis 
(Schlemmer et al., 2015). Frequencies of transitions between wake and sleep states are 
displayed in form of transition matrices for each OSA severity category group and the control 
group, where frequencies are marked by color (variation from zero up to twenty transitions). 
Schlemmer et al. identified two-step transitions as suitable for further analysis, after they 
worked with Markov chains (Schlemmer et al., 2015). A Markov process is a stochastic 
process, based on the assumption that future events are not affected by the past. Two-step 
transitions comprise three symbols (e.g. the pattern wake→N1→wake). We present the 
frequencies of the 25 most common transition patterns per night for each disease severity 









An analysis of variance (ANOVA) with post-hoc Tukey Test was performed to test for 
differences in clinical and traditional sleep data regarding OSA severity and controls. We 
examined differences in exponential decay times by consideration of standard deviations. 
The influence of OSA severity and potential confounders on transition patterns was tested by 
multivariate analysis of variance (MANOVA) restricted to subjects investigated in Antwerp 
(n=808), with the 25 most common two-step-transition patterns as dependent variables and 
four categories (OSA severity, age-group, gender, BMI-group) as independent variables. 
Analysis was limited to main effects. Pillai’s trace was chosen to evaluate significance and 
partial η2 was considered as indicator, how much variance of the dependent variable 
(transition) is explained by the independent variable (group). Effect sizes were interpreted 
based on benchmarks for small (η2=0.01), medium (η2=0.06) and large (η2=0.14) effects 
provided by Cohen (Cohen, 1988). Multiple comparisons were performed by a Tukey-test. 
Subsequently, we performed t-tests to examine differences in traditional metrics and two-
step transitions (only significant transitions regarding OSA severity) between patients with 
diagnosed and without diagnosed arterial hypertension and between patients with (ESS>10) 
and without (ESS≤10) daytime sleepiness. Effect sizes were indicated by Cohen’s d, based 
on benchmarks for small (d=0.2), medium (d=0.5) and large (d=0.8) effects provided by 
Cohen. Cohen’s d is calculated based on standardized mean differences and a pooled 
standard deviation. (Cohen, 1988; Lakens, 2013). Regarding arterial hypertension, we 
focussed on patients with high systolic (RRsyst.≥140 mmHg) and diastolic blood pressure 








the testing for daytime sleepiness and diastolic blood pressure in a multicenter cohort 
(validation cohort). Level of significance was always set at p<0.05. 
 
Results 
Patients from the development cohort 
Clinical data as well as sleep data of OSA severity categories and a control group are 
presented in table 1. The highest values for age and BMI were found in severe OSA patients. 
Severe OSA patients spent more time in N1 and N2, whereas time in N3 and REM was 
reduced. The total number of transitions was higher in moderate and severe OSA patients 
compared with controls. However, neither TST nor SE showed significant differences 
amongst subgroups. Interestingly, the average ESS results of OSA patients did not differ 
from controls. 
Cumulative distributions of wake and sleep states 
The cumulative distributions of wake episode durations with respect to OSA severity are 
presented in figure 1, both in a double logarithmic and a semi logarithmic plot. For all three 
OSA groups and the control group, the decay was very well described by power-law fits up to 
durations of approximately 30 minutes (represented by straight lines in panel a). The ratios of 
fitting errors were under unity for all subgroups, indicating superiority for power-law fits, see 
table 2. The power law exponent α was nearly the same for all groups (α = 1). Yet, minor 
deviations were observed not only in relationship to OSA severity (0.95 in moderate and 1.05 
in severe OSA), but also in terms of BMI and age. The cumulative distributions of sleep state 








described by exponential fits up to durations of approximately 90 minutes (represented by 
dashed lines). The ratios of fitting errors showed a strong advantage of exponential 
distributions compared to power-law distributions for all groups. Specifically, ratios of fitting 
errors varied from 28.9 in severe OSA and 152.8 in mild OSA, see table 2. The exponential 
decay was nearly the same (τ ≈ 24 min) for almost all groups, except for age. With increasing 
age, the exponential decay decreased. Young patients had τ =27.28 min (68% confidence 
interval=27.20, 27.36), middle aged 23.84 min (68% confidence interval=23.79,23.89), and 
elderly 22.55 min (68% confidence interval=22.49,22.61).  
 
The influence of OSA severity and potential confounders on transition patterns 
Transition matrices showing frequencies of one-step transitions between wake and sleep 
states for each OSA severity category and the control group are presented in figure 3, where 
frequencies are marked by color. In all groups, the most frequent transitions happened 
between wake and light sleep. In healthy controls, transitions between N1 and N2 were less 
salient. To evaluate the influence of OSA severity and potential confounders on transition 
patterns, we performed a MANOVA (n=808). In our model, we focused on main effects of our 
independent variables OSA severity, age-group, gender, BMI-group. The 25 most frequent 
two-step transitions were our dependent variables (Figure 4). Pillai’s trace was significant for 
each of the four groups. The transition N1→N2→wake (p<0.001, partial η2=0.025) was 
associated with OSA severity, see table 3. In controls, N1→N2→wake transitions were less 
frequent (5.6±3.6) compared to both moderate (7.1±5.1; p=0.048) and severe (8.0±5.5; 
p<0.001) OSA patients. Furthermore, severe OSA patients had more N2→wake→N2, 








However, the strongest relation was found for the transitions wake→N1→wake (p<0.001, 
partial η2=0.045) and N1→wake→N1 (p<0.001, partial η2=0.037) regarding age. Older 
patients had significantly more wake>N1>wake transitions (8.0±8.2) than middle aged 
(4.8±4.9, p<0.001) and young patients (4.1±5.2, p<0.001). Likewise, N1→wake→N1 
transitions were more frequent in patients 60 years or older. Furthermore, gender showed a 
relation to the pattern N2→N3→wake (p<0.001, partial η2 = 0.039). Women had significantly 
(p<0.001) more transitions (2.5±2.1) than men (1.5±1.5). The influence of BMI on transition 
patterns was extremely mild. The largest effect was observed for the transition 
REM→wake→N1 (p=0.010, partial η2=0.011), which was the lowest in obese patients. 
However, gender had an even stronger effect (partial η2=0.024). All significant transitions 
regarding age, BMI and gender are presented in the supplement (S1).  
Two-step transitions in hypertensive patients and in patients with daytime sleepiness  
We analyzed traditional polysomnographic metrics and two-step transitions in OSA patients 
(n=703) with hypertension and sleepiness. Hypertensive patients (n=220) had a shorter TST 
(370.3±67.1 min vs. 387.2±62.6 min, p=0.001, d=0.260), a lower SE (83.8±11.6 % vs. 
87.5±9.7 %, p<0.001, d=0.346), more WASO (72.0±53.4 min vs. 55.1±42.5 min, p<0.001, 
d=0.350) and more NASO (25.7±15.7 vs. 23.3±12.7, p=0.042, d=0.168) compared to 
normotensive ones (n=483). The total number of one-step and two-step transitions did not 
differ in hypertensive patients. Subsequently, we focused separately on high systolic 
(RRsyst.≥140 mmHg) and diastolic (RRdiast.≥90 mmHg) blood pressure. 201 patients with 
high systolic pressure (103 were diagnosed as hypertensive) showed no differences in both 
traditional metrics and two-step transitions. In 159 patients with high diastolic blood pressure 








(1.4±1.6, p=0.018, d=0.242) compared to patients with normal diastolic pressure (1.8±1.7). In 
patients with excessive daytime sleepiness (n=281) the total number of transitions 
(100.9±48.5 vs. 91.1±39.4, p=0.005, d=0.222) was elevated compared to non-sleepy 
patients (n=422). In addition, transition patterns of N2→N1→N2 (7.0±13.5 vs. 4.7±9.0, 
p=0.016, d=0.200), N1→N2→N1 (6.5±13.3 vs. 4.5±9.3, p=0.028, d=0.174) were more 
frequent in patients with daytime sleepiness. Interestingly, TST (390.7±63.1 min vs. 
376.0±64.7 min, p=0.003, d=0.230) and SE (87.3±10.2 % vs. 85.7±10.6 %, p=0.039, 
d=0.154) were also higher in patients with daytime sleepiness.  
 
Validation cohort 
To validate the association between sleep-stage transitions and the outcome parameters like 
daytime sleepiness and elevated diastolic blood pressure, we repeated the analysis in 425 
OSA patients from 10 different centers. Compared to the development cohort (single center), 
heterogeneity in anthropometrics and sleep data was observed. Patients in the multicenter 
cohort were older (54.0±11.4 y vs. 49.7±11.0 y, p<0.001), had a higher AHI (42.3±25.1/h vs. 
29.7±21.1/h, p<0.001) and a shorter TST (358.6±101.6 min vs. 381.9±64.4 min, p<0.001). A 
complete comparison between the development cohort and the validation cohort is presented 
in the supplement (S2). In the multicenter cohort, N2→N1→N2, N1→N2→N1, N2→N3→N2, 
and N3→N2→N3 transitions were more frequent compared to the single center cohort and to 
the control group (Figure 5). In 152 patients of the multicenter cohort with high diastolic blood 
pressure we identified higher transition rates for N2→N1→N2 (p=0.023, d=0.239), 








(p=0.020, d=0.231) and an increased percentage of N1 (p<0.001, d=0.403) compared to 
normotensive patients. Fewer N2→REM→wake transitions (p=0.006, d=0.208) and reduced 
N3 (p=0.001, d=0.331) and REM (p=0.013, d=0.255) were also observed. The transition 
pattern N2→N3→wake did not differ compared to normotensive patients. In 194 patients of 
the multicenter cohort with daytime sleepiness we observed more N2→wake→N2 (p<0.001, 
d=0.406) and wake→N2→wake (p<0.001, d=0.402) transitions and an increased percentage 
of N2 (p=0.014, d=0.246) compared with non-sleepy individuals. In addition, fewer 
N1→N2→N3 (p=0.020, d=0.235), N1→N2→REM (p=0.001, d=0.322) and N2→REM→N1 
(p=0.010, d=0.240) could be observed. The transition patterns N2→N1→N2 and 
N1→N2→N1, identified in the single center cohort, did not differ significantly. 
 
Discussion 
In our study we identified three major findings. First, independent of OSA severity and 
potential confounders, wake state durations followed a power-law distribution, while sleep 
state durations were characterized by an exponential distribution. Second, sleep dynamics 
are not only influenced by OSA severity, but also age and gender confound sleep-stage 
transitions in unique ways. Third, we describe an association between sleep-stage transition 
patterns and relevant OSA-related problems like arterial hypertension and daytime 
sleepiness. 
Regarding the distributions of wake and sleep durations, our findings confirm that wake 
states follow a power-law distribution, while sleep states follow an exponential distribution, 








nature and implies a long-term memory. Specifically, the duration of the current wake-state is 
influenced by the durations of all previous wake episodes (Lo et al., 2004; Newman, 2005). 
The corresponding control system seems to work unimpaired in OSA patients and 
independent of OSA severity, while it is altered in narcolepsy patients (Zhang et al., 2017). 
For the durations of sleep states, we observed exponential distributions with characteristic 
time scales (τ ≈ 24 min). With age, the exponential decay time decreases (from τ = 27.28 min 
in young to τ = 22.55 min in elderly). These findings agree with results from Zhang et al. 
(Zhang et al., 2017). However, we noticed tremendous variations of the accuracy of the fits 
regarding all groups, but especially in relationship to OSA severity. These deviations could 
indicate limitations in describing wake states by power-law and sleep states by exponential 
distributions. An alternative approach favors multi-exponential processes for both wake and 
sleep durations (Bianchi et al., 2010). Based on this, Bianchi et al. introduced a Markov 
model, based on multi-exponential stage dynamics and probabilistic transitions, to quantify 
sleep fragmentation (Bianchi et al., 2012). This model was limited, because it solely 
considered exit rates to determine the mean time spent in any state and disregarded the 
influences of previous transitions. Our approach to analyze two-step transition could be 
extended and incorporated into this Markov sleep model. 
We observed unique two-step transitions dependent on OSA severity, age and gender. 
Severe OSA patients had notably more N1→N2→wake, N2→wake→N2 and N2→N1→N2 
transitions compared with controls, which agrees with results obtained by Schlemmer et al. 
and implies a N2 vulnerability (Schlemmer et al., 2015). A N2 vulnerability was also found in 
insomnia patients (Wei et al., 2017). In patients over 60, we have seen significantly higher 








N2→N3→wake transitions than men. The findings regarding potential confounders of sleep 
apnea coincide with results obtained by Redline et al., who stated a greater influence on 
sleep architecture by age and gender compared to sleep disordered breathing and a weak 
influence of BMI (Redline et al., 2004). However, the effects must be interpreted as small 
(partial η2 always <0.06) (Cohen, 1988). Yet, some references recommend not using 
Cohen’s benchmarks to interpret effect sizes. Instead, they suggest relating results to similar 
literature and explaining practical consequences. (Olejnik and Algina, 2003, Thompson, 
2007, Lakens, 2013). Chervin et al. observed a shorter mean N2 duration in children with 
OSA with a large effect size (d of approximate 1.15 at baseline and 0.97 at a one year follow 
up), which is impressive, suggesting the potential of dynamic parameters (Chervin et al., 
2009). Admittedly, we observed smaller effect sizes regarding transition patterns and their 
association to OSA severity and potential confounders. Nevertheless, based on these 
transition patterns with small effect sizes, we could link sleep fragmentation directly to OSA-
related clinical outcomes.  
In the development cohort, the transition pattern N2→N3→wake was the only 
polysomnographic sleep parameter distinguishing OSA-patients with high diastolic blood 
pressure from patients with normal diastolic blood pressure. Interestingly, the same pattern 
was significantly lower in men (male predominance with 84.9% in the group of OSA patients 
with high diastolic blood pressure). In the validation cohort, we observed higher transition 
rates for N2→N1→N2 and N1→N2→N1 and a reduced time in N3. These findings could 
result from a distinct N2 vulnerability due to more severe disease (AHI/h: 42.3±25.1 vs. 
29.7±21.1, p<0.001) in the validation cohort. However, small effect sizes (d always under 








limit this observation, especially since different β-blockers influence sleep in various manner 
(Yilmaz et al., 2008). In this context, it is further necessary to consider the possible 
influences of scoring differences in the validation cohort. A rather low scoring agreement in 
OSA patients (Danker-Hopfe et al., 2004; Penzel et al., 2003), aggravated by pooling 
scorings from different centers, could impair an analysis of two-step transitions. Future 
studies could compare our results with recordings scored by computerized algorithms. 
Despite these unresolved issues, this association of sleep fragmentation and diastolic 
hypertension is impressive, since OSA-related arterial hypertension is predominantly 
diastolic (Baguet, 2005).  
In patients of the development cohort with daytime sleepiness, a higher frequency of 
N1→N2→N1 and N2→N1→N2 transitions could be observed. Interestingly, TST and SE 
were higher in sleepy patients, which agrees with previous results (Roure et al., 2008). The 
highest effect sizes (still small according to Cohen’s benchmarks) were observed for 
N2→wake→N2 (d=0.406) and wake→N2→wake transitions (d=0.402) in the validation 
cohort. Nevertheless, we observed higher frequencies of alternating (symmetric) patterns in 
sleepy patients both in the development cohort (e.g. N2→N1→N2) and in a validation cohort 
(e.g. N2→wake→N2). Interestingly, asymmetry in sleep stage transitions was described to 
be fundamental in sleep dynamics. Furthermore, decreased asymmetry was observed in 
OSA patients (Lo et al., 2013). We observed not only higher frequencies of symmetric 
patterns (e.g. N2→wake→N2 and N2→N1→N2) in severe OSA patients but also an 
association between these alternating transition patterns to sleepiness. Admittedly, we 
simplified sleepiness very strongly by just comparing patients with ESS > 10 and ≤ 10. 








and restfulness, lighter and restless sleep was associated with a higher sleep-stage 
transition rate (Laffan et al., 2010). In combination with our results, it may be suggested that 
sleep-stage transition analysis and particularly the analysis of alternating patterns related to 
simplified measurements of sleepiness could help to evaluate sleep continuity.  
Our retrospective study has several strengths and limitations. Our study is based on ESADA. 
This large and standardized database enabled both a single-center analysis to minimize a 
possible influence of scoring differences and a multicenter analysis for validation. We could 
ensure a large patient cohort with different OSA degrees, strict exclusion criteria and without 
any missing values for ESS or arterial hypertension. As limitation we have to state that 
patients were analyzed only for a single night under laboratory conditions. Since light off and 
light on times were not available consistently, we could not assess sleep latency and had to 
exclude sleep latency when calculating sleep efficiency. Despite an exclusion of patients with 
psychiatric disease, a few patients used antidepressants or another medication which may 
impact sleep and sleep stage transitions (Wilson and Argyropoulos, 2005). Furthermore, 
patients of the development cohort and validation cohort were not matched for age, BMI or 
gender.  
Conclusion 
Our analysis of sleep architecture revealed that wake states follow a power-law distribution, 
while sleep states follow an exponential distribution, independent of OSA severity or potential 
confounders. Effects of OSA severity and potential confounders on sleep architecture are 
small, but transition patterns still link sleep fragmentation directly to OSA-related clinical 
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OSA= obstructive sleep apnea 
TST= total sleep time 
ESS= Epworth sleepiness scale 
NASO= number of awakenings 
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AHI= apnea-hypopnea index 
PAP-therapy= positive airway pressure therapy 
CSA= central sleep apnea 
BMI= body mass index 
PSG= polysomnography 
AASM= American Academy of Sleep Medicine 
SE= sleep efficiency 
WASO= wakefulness after sleep onset 
NASO= number of awakenings 
TRANS= total number of transitions 
ANOVA= analysis of variance 














Figure 1. Cumulative distributions of wake durations for each OSA group and for controls. 
Grey bars indicate the analyzed interval from 1 to 30 min. In (a) dashed lines represent the 
best fits for a power law in a double logarithmic plot. In (b) dashed lines represent the best 
fits for an exponential distribution in a semi logarithmic plot. Independent of OSA severity, 
wake durations rather followed power law than exponential distributions. 
Figure 2. Cumulative distribution of sleep durations for each OSA group and for controls are 
plotted with their best fit for exponential distribution in this semi logarithmic plot. The grey bar 
indicates the analyzed interval from 3 to 90 min. 
Figure 3. Average number of transitions per night between wake and sleep states for each 
OSA severity group and the control group. Transitions are from the states noted on the left to 
the states noted on the top. The average number of transitions is color coded for each 
square. In controls, transitions between N1 and N2 were less salient. 
Figure 4. Representation of the 25 most frequent two-step transitions in descending order for 
each OSA severity group and for the control group. Grey bars indicate the average number 
in all OSA groups and determine the order in the horizontal axis. 
Figure 5. Representation of the 25 most frequent two-step transitions in descending order for 
the laboratory of Antwerp (development cohort), a multicenter cohort (validation cohort) and 
controls. Grey bars indicate the average number in all OSA groups and determine the order 
in the horizontal axis. 
 
 
0 1 0 2 0 3 0 4 0 5 01 1 0
- 2 . 5
- 2 . 0
- 1 . 5
- 1 . 0
- 0 . 5
0 . 0
  
W a k e  D u r a t i o n  t  [ m i n ]













W a k e  D u r a t i o n  t  [ m i n ]
( a )
0 2 0 4 0 6 0 8 0 1 0 0 1 2 0 1 4 0 1 6 0 1 8 0
- 3 . 0
- 2 . 5
- 2 . 0
- 1 . 5
- 1 . 0
- 0 . 5











S l e e p  D u r a t i o n  t  [ m i n ]
n u m b e r  o f  t r a n s t i o n s  p e r  n i g h t
  
 f r o m :WN 1N 2N 3R E M
t o :  N 2    R E M      W     N 2    R E M      W     N 2    R E M      W      N 2    R E M   
M i l d  O S A        M o d .  O S A      S e v e r e  O S A       C o n t r o l s

































































































































































































Table 1. Clinical groups and sleep data (mean).  




Number 105 209 222 272 
Age (years) 43.6 47.4 49.7 51.6 
BMI (kg/m2) 26.7 27.5 29.1 31.5 
Gender* (males/females) 64/41 156/53 175/47 239/33 
AHI (#/h) 2.4 9.6 22.4 51.1 
TST (min) 381.9 389.1 378.7 379.0 
SE (% TST) 87.4 87.7 85.5 85.9 
N1 (% TST) 6.8 7.2 8.2 10.4 
N2 (% TST) 51.0 49.8 50.6 55.2 
N3 (% TST) 21.0 21.8 20.8 16.3 
REM (% TST) 21.3 21.3 20.4 18.1 
WASO (min) 54.4 54.6 64.4 61.6 
NASO 19.8 21.2 23.5 26.7 
TRANS 79.8 84.9 93.9 103.7 
ESS 9.1 9.3 9.3 9.8 
 
Notes: BMI=body mass index; ESS=Epworth sleepiness scale; AHI=apnea-hypopnea index; 
TST=total sleep time; SE=sleep efficiency; WASO= wake after sleep onset; NASO= number 
of awakenings after sleep onset; TRANS=number of transitions.                                        
Bold numbers represent significance compared to controls (Level of significance <0.05 
according to an ANOVA and Tukey-test for multiple comparisons). 
*Pearson Chi2: p<0.001 
Table 2. Results for power-law and exponential distribution fits 
in each subset. The power-law exponent α is presented in 
column 1. For wake states, the ratio of fitting errors (Xp/Xe) 
indicates an advantage for power laws, whereas sleep states 
are better described by exponential distributions. Further sleep 
states are presented with the exponential decay time τ(min). 
  Wake States Sleep States 
Group α Xp/Xe τ (min) Xp/Xe 
Male 1.02 0.05 24.39 114.4 
Female 1.04 0.07 24.33 118.6 
<40y 1.01 0.03 27.28 85.2 
40y to 60y 1.05 0.05 23.84 153.5 
60y and Older 0.99 0.11 22.55 84.2 
Mild OSA 1.03 0.03 23.92 152.8 
Moderate OSA 0.95 0.01 24.78 99.7 
Severe OSA 1.05 0.27 24.39 28.9 
Normal Weight 1.09 0.06 23.87 156.4 
Overweight 0.99 0.02 24.47 111.8 
Obesity 1.04 0.13 24.52 79.2 
Controls 1.17 0.05 24.42 93.8 
 
 
 Table 3. Significant transitions regarding OSA severity after performing MANOVA. Bold numbers 
indicate significance to controls. Partial Eta-Squared states, how much variance of the dependent 
variable (transition) is explained by the independent variables (group). Transitions are presented in 
descending order dependent on partial eta-squared. 









p partial η2 
N1-N2-wake 5.6±3.6 6.3±4.3 7.1±5.1 8.0±5.5 <0.001 0.025 
N2-wake-N2 3.1±6.4 3.1±4.0 3.9±4.8 5.7±10.3 <0.001 0.022 
N2-N1-N2 3.8±5.5 3.8±5.3 5.2±7.9 7.4±15.5 0.001 0.020 
wake-N2-wake 2.3±6.5 2.1±3.1 2.9±4.0 4.6±9.7 0.002 0.019 
N1-N2-N1 3.3±5.5 3.5±5.1 4.7±7.9 7.1±15.6 0.002 0.019 
N2-N3-wake 1.9±1.8 2.1±1.9 1.7±1.6 1.4±1.5 0.005 0.016 
N1-N2-N3 3.0±1.7 3.4±1.9 3.3±2.0 2.8±2.0 0.005 0.016 
N2-REM-N1 1.0±1.4 0.9±1.1 1.3±1.7 1.0±1.4 0.008 0.015 
N2-REM-wake 2.7±2.1 2.7±1.7 2.5±1.7 2.2±1.8 0.013 0.013 
N2-wake-N1 6.0±3.7 6.6±3.4 7.3±5.2 7.9±5.3 0.016 0.013 
N1-N2-REM 2.8±1.7 2.6±1.6 2.7±1.8 2.3±1.7 0.034 0.011 
 
Note: Level of significance was set at 0.05. 
 S1. Significant transitions regarding age, BMI and gender after performing MANOVA. Bold 
numbers indicate significance respectively age 60 and older and obesity. Partial Eta-Squared 
states, how much variance of the dependent variable (transition) is explained by the independent 
variables (group). Transitions are presented in descending order, dependent on partial eta-
squared and for each group separately. 
2-step transition Age-Group 
 Under 40 
N=168 
40 to 60 
N=499 
60 and older 
N=141 
p partial η2 
wake-N1-wake 4.1±5.2 4.8±4.9 8.0±8.2 <0.001 0.045 
N1-wake-N1 4.6±5.7 5.1±5.2 8.1±8.3 <0.001 0.037 
REM-wake-N1 2.2±1.8 2.7±1.9 2.6±2.2 0.001 0.019 
N2-REM-wake 2.2±1.6 2.6±1.9 2.3±1.7 0.002 0.016 
wake-REM-wake 0.7±1.5 1.2±2.8 1.9±4.1 0.002 0.015 
N2-REM-N1 1.3±1.5 1.0±1.4 0.8±1.2 0.005 0.013 
N2-wake-N2 3.0±3.6 4.8±8.5 3.5±5.2 0.006 0.013 
REM-wake-REM 1.1±1.8 1.6±3.0 2.2±4.2 0.010 0.012 
N3-wake-N1 1.0±1.3 0.9±1.1 1.2±1.4 0.007 0.012 
N1-N2-N3 3.2±1.9 3.0±1.9 3.5±2.3 0.017 0.010 
N2-REM-N2 1.3±1.8 1.1±2.0 0.7±1.2 0.026 0.009 
wake-N2-wake 2.0±2.9 3.6±8.0 2.9±4.5 0.026 0.009 
wake-N1-N2 10.6±5.9 11.4±5.3 12.5±6.3 0.044 0.008 
 
2-step transition BMI-Group 






p partial η2 
REM-wake-N1 2.7±2.0 2.8±2.1 2.3±1.8 0.010 0.011 
N1-N2-N3 3.1±1.8 3.3±2.0 2.9±1.9 0.030 0.009 
 
 





p partial η2 
N2-N3-wake 1.5±1.5 2.5±2.1 <0.001 0.039 
REM-wake-N1 2.7±2.0 2.1±1.9 <0.001 0.024 
wake-N2-N3 0.9±1.3 1.4±1.8 <0.001 0.022 
N2-REM-wake 2.6±1.8 2.2±1.8 0.002 0.012 
N3-wake-N1 0.9±1.1 1.3±1.5 0.004 0.010 
N1-N2-N3 3.0±1.9 3.5±2.1 0.010 0.008 
N1-wake-N1 5.8±6.4 4.3±4.4 0.009 0.009 
wake-N1-wake 5.5±6.2 4.1±4.1 0.009 0.009 
 
Note: Level of significance was set at 0.05. 
S2. Clinical and sleep data (mean±SD) of the development cohort 
and the validation cohort. 
 Development cohort Validation cohort 
Number 703 425 
Age (years) 49.7±11.0 54.0±11.4 
BMI (kg/m2) 29.5±5.0 32.9±6.4 
Gender* (males/females) 570/133 335/90 
AHI (#/h) 29.7±21.1 42.3±25.1 
TST (min) 381.9±64.4 358.6±101.6 
SE (% TST) 86.3±10.5 86.9±12.0 
N1 (% TST) 8.8±7.7 14.8±13.8 
N2 (% TST) 52.1±11.3 54.1±19.5 
N3 (% TST) 19.4±10.0 17.8±15.1 
REM (% TST) 19.8±6.3 13.3±7.6 
WASO (min) 60.4±46.8 52.9±50.2 
NASO 24.0±13.7 15.8±16.9 
TRANS 95.0±43.5 83.5±85.0 
ESS 9.5±5.1 10.1±5.1 
 
Notes: BMI=body mass index; ESS=Epworth sleepiness scale; AHI=apnea-hypopnea index; 
TST=total sleep time; SE=sleep efficiency; WASO= wake after sleep onset; NASO= number 
of awakenings after sleep onset; TRANS=number of transitions. 
Bold numbers represent significance compared to Development Cohort (Level of significance 
<0.05 according to t-test).  
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Center of Sleep and Wake Disorders, Sahlgrenska Academy, Gothenburg University, Göteborg, 
Sweden 
• Hedner J, Sleep Disorders Center, Pulmonary Department, Sahlgrenska University Hospital, and 
Center of Sleep and Wake Disorders, Sahlgrenska Academy, Gothenburg University, Göteborg, 
Sweden 
 
15. Grenoble, France 
• Pépin JL, Université Grenoble Alpes, INSERM HP2 (U1042) and Grenoble University Hospital, 
Grenoble, France 
• Levy P, Université Grenoble Alpes, INSERM HP2 (U1042) and Grenoble University Hospital, 
Grenoble, France 
• Bailly S, Université Grenoble Alpes, INSERM HP2 (U1042) and Grenoble University Hospital, 
Grenoble, France 
 
16. Haifa, Israel (inactive) 
 Lena Lavie and Peretz Lavie, Centre for Sleep Medicine, Technion Institute of Technology, Haifa, 
Israel 
 
17. Hamburg, Germany 




18. Izmir, Turkey 
• Basoglu OK, Department of Chest Diseases, Ege University, Izmir, Turkey 
• Tasbakan MS, Department of Chest Diseases, Ege University, Izmir, Turkey 
 
19. Klapeida, Lithuania (inactive) 
• Varoneckas G, Institute Psychophysiology and Rehabilitation, Palanga, Lithuania 
 
20. Kosice, Slovakia 
• Joppa P, Department of Respiratory Medicine and Tuberculosis, Faculty of Medicine, P.J.Safarik 
University and L. Pasteur University Hospital, Kosice, Slovakia 
• Tkacova R, Department of Respiratory Medicine and Tuberculosis, Faculty of Medicine, 
P.J.Safarik University and L. Pasteur University Hospital, Kosice, Slovakia 
 
21. Lisbon, Portugal 
 Staats R, Department of Respiratory Medicine, Hospital de Santa Maria, Lisbon, Portugal 
 
22. Lleida, Spain 
• Barbé F,  Servei Pneumologia  Hospital Arnau de Vilanova and Hospital Santa Maria, Lleida, and 
CIBERes, Madrid,  Spain 
 
23. Milano, Italy 
• Lombardi C, Istituto Auxologico Italiano, IRCCS, Department of Cardiovascular, Neural and 
Metabolic Sciences, St. Luke Hospital, Milan  &  Department of Medicine and Surgery; University 
of Milano-Bicocca, Milan, Italy. 
• Parati G, Istituto Auxologico Italiano, IRCCS, Department of Cardiovascular, Neural and 
Metabolic Sciences, St. Luke Hospital, Milan  &  Department of Medicine and Surgery; University 
of Milano-Bicocca, Milan, Italy. 
 
24. Porto, Portugal 
 Marta Drummond, Pulmonology Department Hospital São João, Medicine Faculty of Porto 
University, Porto, Portugal 
 Mafalda van Zeller, Pulmonology Department Hospital São João, Medicine Faculty of Porto 
University, Porto, Portugal 
 
25. Palermo, Italy 
• Bonsignore MR, PROMISE Dept., University of Palermo, Palermo, Italy  
• Marrone O, CNR Istituto per la Ricerca e l'Innovazione Biomedica, Palermo, Italy  
 
26. Paris, France 
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• Escourrou P, Service dÉxplorations Fonctionnelles Multidisciplinaires Hospital Antoine Beclere, 
Clamart, France 
• Roisman G, Unité de Médecine du Sommeil, Hopital Antoine-Beclere, Clamart, France 
• Petitjean M, Unité de Médecine du Sommeil, Hopital Antoine-Beclere, Clamart, France 
 
27. Prague, Czech Republic 
• Pretl M,Centre for Sleep and Waking Disorders, Department of Neurology, First Faculty of 
Medicine, Charles University, Prague, and Inspamed, Neurology and Sleep Laboratory, Prague, 
Czech Republic 
 
28. Riga, Latvia (inactive) 
• Vitols A, Institute of Cardiology, University of Latvia, Riga, Latvia 
 
29. Split, Croatia 
• Dogas Z, Sleep Medicine Center, Department of Neuroscience, University of Split School of 
Medicine, Split, Croatia 
• Galic, T, Sleep Medicine Center, Department of Neuroscience, University of Split School of 
Medicine, Split, Croatia 
 
30. Thessaloniki, Greece 
 Pataka A, Respiratory Failure Unit, G. Papanikolaou Hospital, Thessalonika, Greece 
 
31. Turku, Finland 
• Anttalainen U, Division of Medicine, Department of Pulmonary Diseases, Turku University 
Hospital and Sleep Research Centre, Department of Pulmonary Diseases and Clinical Allergology, 
University of Turku, Finland 
• Saaresranta T, Division of Medicine, Department of Pulmonary Diseases, Turku University 
Hospital and Sleep Research Centre, Department of Pulmonary Diseases and Clinical Allergology, 
University of Turku, Finland 
 
Warsaw, Poland 
32. Institute of Tuberculosis and Lung Diseases 
 
Sliwinski P, 2nd Department of Respiratory Medicine, Institute of Tuberculosis and Lung Diseases, 
Warsaw, Poland 
Plywaczewski R, 2nd Department of Respiratory Medicine, Institute of Tuberculosis and Lung 
Diseases, Warsaw, Poland 
 




 Bielicki P, Department of Internal Medicine, Pneumonology and Allergology, Medical University 
of Warsaw, Warsaw, Poland 
 Jan Zielinski, Department of Internal Medicine, Pneumonology and Allergology, Warsaw Medical 
University, Warsaw, Poland (†) 
 
Mainz, Germany 
 Haralampos Gouveris, ENT department at Mainz University Hospital, Mainz, Germany 
 
Timisoara, Rumania 
 Stefan Mihaicuta, Sleep Disorders Center, University Hospital, Timisoara, Rumania 
 
Centers in the start-up process:  
 Dries Testelmans, Sleep Disorders Centre, University Hospital Gasthuisberg, Leuven, Belgium 
 Winfried Randerath, Sleep Disorders Centre, Pulmonary Clinic, Solingen, Germany 
 
